

Published in final edited form as:

*Mol Ther Methods Clin Dev.* ; 3: . doi:10.1038/mtm.2014.49.

## SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE

Waldy San Sebastian<sup>1,\*</sup>, Adrian P. Kells<sup>1,\*</sup>, John Bringas<sup>1</sup>, Lluís Samaranch<sup>1</sup>, Piotr Hadaczek<sup>1</sup>, Agnieszka Ciesielska<sup>1</sup>, Michael Macayan<sup>1</sup>, Phillip J. Pivrotto, John Forsayeth<sup>1</sup>, Sheryl Osborne<sup>2</sup>, J Fraser Wright<sup>3,4</sup>, Foad Green<sup>1</sup>, Gregory Heller<sup>1</sup>, and Krystof S. Bankiewicz<sup>1</sup>

<sup>1</sup>Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA

<sup>2</sup>Consultant

<sup>3</sup>Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA

<sup>4</sup>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

### Abstract

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare, autosomal-recessive neurological disorder caused by mutations in the *DDC* gene that leads to an inability to synthesize catecholamines and serotonin. As a result, patients suffer compromised development, particularly in motor function. A recent gene replacement clinical trial explored putaminal delivery of recombinant adeno-associated virus serotype 2 vector encoding human AADC (AAV2-hAADC) in AADC-deficient children. Unfortunately, patients presented only modest amelioration of motor symptoms, which authors acknowledged could be due to insufficient transduction of putamen. We hypothesize that, with the development of a highly accurate MRI-guided cannula placement technology, a more effective approach might be to target the affected mid-brain neurons directly. Transduction of AADC-deficient dopaminergic neurons in the substantia nigra and ventral tegmental area with locally infused AAV2-hAADC would be expected to lead to restoration of normal dopamine levels in affected children. The objective of this study was to assess the long-term safety and tolerability of bilateral AAV2-hAADC MRI-guided pressurized infusion into the mid-brain of non-human primates. Animals received either vehicle, low or high AAV2-hAADC vector dose and were euthanized 1, 3 or 9 months after surgery. Our data indicate that effective mid-brain transduction was achieved without untoward effects.

---

Correspondence should be addressed to K. S. B. (Krystof.Bankiewicz@ucsf.edu). Department of Neurological Surgery, University of California San Francisco, 1855 Folsom Street, MCB 226, San Francisco, CA 94103-0555. Tel: (415) 502-3132; Fax: (415) 514-2864.

\*These authors contributed equally to this work

### CONFLICT OF INTEREST

The authors declare no conflict of interest.

## Keywords

AAV2-hAADC; MRI-guided; pressurized infusion; AADC deficiency

---

## INTRODUCTION

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare recessive genetic disorder in which mutations in the *DDC* gene (DOPA decarboxylase, NG\_008742) lead to deficient synthesis of catecholamines (dopamine, norepinephrine, epinephrine) and serotonin. Over 100 cases with more than 30 different mutations in the AADC gene (<http://www.biopku.org>) have been identified worldwide<sup>1, 2</sup> since the original description of the disorder in 1990<sup>3</sup>. Affected children suffer chronic and severe motor, cognitive, and behavioral disability. The most prominent neurological symptoms are motor: hypokinesia, hypotonia, oculogyric crises, involuntary movements and motor developmental delay<sup>4</sup>. Because of the lack of AADC, which catalyzes conversion of levodopa (L-DOPA) to dopamine, motor symptoms do not respond to therapy with L-DOPA, in contrast to the positive response observed in Parkinson's disease (PD) and some other inborn errors of dopamine metabolism<sup>5, 6</sup>. Most patients with AADC deficiency obtain little if any symptomatic benefit from currently available medical therapies<sup>4</sup>.

In recent years, use of a viral vector, adeno-associated virus type 2 (AAV2), encoding the cDNA of human *DDC* gene (hAADC), has been developed for the treatment of PD. Initial studies have demonstrated that the gene can be safely delivered to the striatum in human subjects via targeted infusion in adult PD patients<sup>7, 8</sup>. More recently, a Phase I clinical study was conducted in children with AADC deficiency<sup>9</sup>. These pediatric patients received a bilateral AAV2-hAADC infusion into the putamen that resulted in moderate motor performance improvement and an increase in 6-[<sup>18</sup>F]fluoro-DOPA uptake, a tracer for AADC, in all subjects. The trial investigators acknowledged that the vector might have only partially covered the putamen accounting for mild motor improvement in patients. Perhaps a more important issue, however, is that AAV2 does not undergo retrograde axonal transport in the brain and putaminally infused vector would not be expected to transduce affected catecholaminergic neurons with any appreciable efficiency<sup>10, 11</sup>. Moreover, anterograde transport of AAV2 and gene product after putaminal infusion results in AADC expression in many non-targeted nuclei such as globus pallidus, subthalamic nucleus and substantia nigra pars reticulata (SNpr)<sup>11, 12</sup>. Unlike in PD, where there is extensive degeneration of dopaminergic nigrostriatal neurons, dopamine transporter (TROPAT) imaging reveals that the nigrostriatal pathway is largely unaffected in AADC deficiency<sup>1</sup>. For all these reasons, we believe that vector should be infused directly into affected nuclei to transduce the AADC-deficient catecholaminergic neurons. This approach requires a level of accuracy of cannula placement that, until recently, was challenging. Accordingly, we have developed an MRI-guided infusion platform in non-human primates (NHP) to achieve improved control of infusate delivery and visualization of therapeutic distribution in the brain<sup>13-15</sup>, and this approach has now been integrated into 2 Phase 1 clinical trials in PD for AAV2-glial cell line-derived neurotrophic factor (NCT01621581) and AAV2-hAADC (NCT01973543).

In this manuscript, we report the safety and tolerability of bilateral AAV2-hAADC real-time image-guided infusion into the mid-brain of adult NHP for up to 9 months after surgery. Our data indicate that this approach results in broad coverage of targeted areas (substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA)) and widespread AADC protein distribution in the striatum can be achieved by dopaminergic neurons without inducing any adverse effects. This study supports testing mid-brain administration of AAV2-hAADC in a clinical study as a possible gene therapy for AADC-deficient patients.

## RESULTS

Two experiments were performed in this study (Table 1): 1) an initial pilot study to examine vector distribution, dose-ranging and initial safety after delivery into the midbrain (N=2) and 2) an Investigational New Drug (IND)-enabling study to assess long-term safety and toxicology of AAV2-hAADC administration to mid-brain [Control group (vehicle, N=4), AAV2-hAADC low-dose group (N=6) and high-dose group (N=6)].

### Infusion performance

In both studies, AAV2-hAADC (N = 14) or vehicle (N = 4) was used to infuse the right and left SNpc and VTA (total of 36 cannula insertions). Up to 46  $\mu$ L of the infusate per hemisphere was infused bilaterally (30  $\mu$ L per side in the toxicology study). Gadolinium-enhanced magnetic resonance images (MRI) from each infusion confirmed that positioning of each cannula was accurate and infusate covered the target area (Fig. 1). All of the 36 infusions were well contained in the target structure with slight reflux seen along the cannula tract in only 2 cases (Fig. 1: V002458, left side; V002254, right side). Three-dimensional reconstructions of the infusate distribution generated from gadolinium signal on MR images showed that both placement and distribution of infusate were very consistent throughout all the animals (Supplementary Fig. 1). As well, the ratio (Vd/Vi) between volume of distribution (Vd) and volume of infusion (Vi) was calculated for each delivery and data were consistent across infusions in both studies. Vd was approximately 2-fold larger than the Vi (pilot study -  $2.23 \pm 0.24$ ; toxicology study -  $2.18 \pm 0.52$ ; Fig. 1 and Supplementary Table 1). No MRI-visible hemorrhages occurred during cannula placement and no adverse events occurred during infusion or subsequently.

### Intervention-related pathology

All animals (N=18) tolerated the AAV dosing procedure with no treatment-related adverse events over a 9-month evaluation period. Hematology, clinical pathology, bodyweight, general activity and behavior remained unchanged. A detailed neurobehavioral assessment was performed at baseline and prior to euthanasia which evaluated cranial nerves, menace, pupil size, bite reflex and strength, strabismus, facial symmetry, cochlear response, head tilt, nystagmus, gait, posture, muscle tone, placing and proprioception. No neurobehavioral abnormalities were observed during the study. Also, gross examination at necropsy showed no remarkable findings related to the experimental treatment. In order to rule out that the absence of adverse effects was due to a non-functional vector, we confirmed AAV2-hAADC performance *in vitro*. Cell-based assay demonstrated increased L-DOPA conversion to dopamine in AAV2-hAADC transduced cells compared to non-transduced ones and

increased dopamine production with increasing multiplicity of infection (MOI, Supplementary Fig. 2)

Hematoxylin and eosin (H&E) staining of the infusion site in pilot animals demonstrated some gliosis located only around the cannula tract (Fig. 2). Similarly, an independent histopathology report on toxicological study animals revealed vacuolated macrophages and gliosis attributable to the infusion procedure itself, because it was present in both control and AAV2-hAADC-treated groups (low- or high-dose) either 1, 3 or 9 months after infusion. Gliosis was less commonly observed at 9 months than at 1 or 3 months and was considered evidence of partial resolution of the damage associated with the infusion procedure. Also, independent histopathological assessment in the toxicology study showed the presence of perivascular mononuclear cell infiltrates only in animals receiving AAV2-hAADC infusion at either low- or high-dose. Nevertheless, they were not considered adverse since animals displayed no symptomatology associated with it. In addition, there were no pathological findings related to infusion with the test article in either the spinal cord or major organ tissues.

### **AADC transgene expression in the brain**

Neurons in the SNpc and VTA express endogenous AADC that made difficult to distinguish transduced neurons from those not transduced in these nuclei. Nevertheless, the distribution and intensity of immunohistochemical AADC staining in the mid-brain of AAV2-hAADC treated animals clearly showed increased AADC expression within the targeted area when compared to mid-brain staining in control animals (Fig. 3A (pilot) and 3B (pivotal toxicology)). In some of the animals, transgenic hAADC signal was noted in the lateral SNpr, normally devoid of AADC, both in double chromogenic (Fig. 3) and double immunofluorescent sections (Supplementary Fig. 3). Histological sections in some of the animals revealed the cannula tract, thereby confirming optimal placement of the cannula and matching observed MRI tracer (Fig. 2) in VTA and medial-lateral SNpc.

AADC immunohistochemical staining was semi-quantitatively analyzed by observers blind to the treatment groups. Coronal brain sections containing either the pre-commissural, commissural, post-commissural striatum, and other basal ganglia nuclei were included in the analysis of the striatal and off-target AADC transgene expression. Transduction of SNpc and VTA neurons resulted in the expression of hAADC in these neurons and the filling of neuronal cytoplasm with the hAADC protein. Thus, since those neurons project axons to the striatum, we detected increased AADC protein in caudate nucleus, putamen and nucleus accumbens in AAV2-hAADC animals compared to control group. Transgenic AADC expression in the striatum was robust, widely distributed and restricted to neuronal fibers (Fig. 4) in both AAV2-hAADC-treated groups, regardless of vector dose or survival time. Four out of 6 animals in both low- and high-dose groups exhibited prominent AADC-immunoreactive (ir) fibers whereas the other 2 animals in each group presented fewer fibers, mainly in the most anterior sections examined (Supplementary Table 2). As expected, animals in the control group displayed no evidence of transgenic hAADC, with AADC-ir restricted to light staining consistent with endogenous expression (Fig. 4 and Table 2). This was further confirmed with double immunofluorescent staining against TH and AADC in

tissue sections containing striatum, where fluorescent intensity of AADC fibers was stronger in AAV2-hAADC-treated animals, regardless of vector dose (Supplementary Fig. 3). With respect to nucleus accumbens, only 2 animals presented a few intense AADC-ir fibers in the core but none in the shell region. There was no significant effect of survival time among AAV2-hAADC or control groups, nor was there a significant vector dose effect on AAV2-hAADC-treated groups.

Distribution of AADC-ir fibers in the striata also matched the cannula positioning in the mid-brain (i.e., slightly anterior positioning of cannula in the mid-brain yielded anterior distribution of fibers in the striatum), explaining the gradient of AADC-ir fibers detected in some of the AAV2-hAADC-treated animals. There were no medium spiny neurons stained for AADC within any of the striata analyzed in either the low- or high-dose groups, indicating that all of the AADC-positive fibers were nigrostriatal projections. Accordingly, double immunofluorescent staining of AADC and DARPP32, a striatal medium spiny neuron marker, showed no DARPP32-ir neurons that co-expressed AADC in the striatum of either group (Supplementary Fig. 4).

Analysis of off-target hAADC expression was performed throughout brain structures including other components of the basal ganglia (i.e., globus pallidus, subthalamic nucleus), hypothalamus, thalamus, brainstem, and spinal cord (Table 3). Most of the off-target expression of the transgene was found in the region dorsal to SN (i.e., red nucleus) and was mostly fibers, although some animals presented a few hAADC-ir neurons in the red nucleus. Sparse fibers and neuronal cells expressed hAADC outside the infusion area and the endogenously expressing structures, but they were restricted to areas proximal to the cannula tracts (Supplementary Tables 3 and 4). Accordingly, some AADC-ir fibers and neuronal cell bodies were visible in the subthalamic nucleus and the thalamus for some of the animals. Many animals exhibited several thick hAADC-ir fibers traversing the corona radiata and the internal capsule, and arising from cortical neurons close to the cannula entry point. Four out of 16 animals contained several hAADC-expressing fibers in the spinal cord that corresponded to projections from either the cortex or the red nucleus. Overall, hAADC transgene expression was restricted to the infusion site and expression outside the target structures (SN and VTA) was limited to tissue around the cannula tracts.

### **Monoamines and their metabolites levels in CSF**

In the toxicological study, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin and 5-hydroxyindoleacetic acid (5-HIAA) were measured in cerebrospinal fluid (CSF) at baseline and at necropsy. Dopamine, DOPAC and serotonin levels in CSF were below the limit of quantification, but HVA and 5-HIAA could be detected in all animals at baseline (Supplementary Table 5). Two animals in the AAV2-hAADC low-dose group had detectable dopamine levels at necropsy (1 and 3 months after vector delivery, respectively). One also had quantifiable levels of serotonin and DOPAC but no change in HVA and 5-HIAA levels. No animals in the AAV2-hAADC high-dose group had detectable levels of either dopamine or serotonin before or after AADC gene transfer nor did they show changes in monoamine metabolites after vector delivery at any time-point (1, 3 or 9 months after vector delivery). Overall, no significant changes in dopamine,

serotonin or their metabolite levels were found in the CSF after AAV2-hAADC gene transfer.

### Vector distribution, AADC protein levels and antibody production

**AAV2-hAADC vector distribution**—Detection of AAV2-hAADC DNA in serum and CSF samples was performed by real-time Q-PCR. The presence of vector sequences in the serum was determined in serum samples collected 4 h after AAV2-hAADC delivery, and in both serum and CSF samples immediately prior to necropsy. Vector DNA copies in serum of control and AAV2-hAADC low-dose groups were below the limit of detection (10 copies/mL) either 4 h after vector delivery or at necropsy. In the high-dose group, 4 animals had AAV2-hAADC DNA in serum 4 h after surgery. Three of them had no detectable DNA at necropsy and the fourth a dramatically lower copy number (7-fold less). One animal that did not exhibit vector DNA in blood serum 4 h after delivery did show DNA levels above the assay sensitivity threshold at necropsy (Supplementary Table 6). No AAV2-hAADC DNA was detected in CSF samples in any of the groups at necropsy. These results indicate some systemic exposure during or immediately after infusion of AAV2-hAADC to the mid-brain.

**AADC protein levels in serum and CSF**—Quantification of AADC levels in serum and CSF samples was performed by sandwich ELISA assay. Serum AADC levels at baseline (prior to AAV2-hAADC delivery) ranged considerably between animals with 9 out of 16 animals showing AADC levels below the detection limit and 2 animals with more than 2.5 ng/mL (Supplementary Table 7). Nine months after AAV2-hAADC delivery, serum and CSF AADC protein level was generally unchanged from baseline, except for 2 animals in the high-dose group and 1 animal in the low-dose group with 7-fold, 2.4-fold and 2.4-fold increases, respectively. However, only 1 animal had detectable serum and CSF AADC protein 3 months after receiving a high dose of AAV2-hAADC and none at baseline. Overall, serum and CSF levels of AADC were generally very low after AAV2-hAADC delivery.

**Neutralizing anti-AAV2 and anti-hAADC antibodies**—Antibody titers for neutralizing antibodies against AAV2 and antibodies against hAADC were measured in serum samples collected prior to surgery (baseline) and at necropsy (1, 3 and 9 months after vector delivery). Anti-AAV2 antibody titers were predominantly 1:25 before brain delivery of either vehicle or AAV2-hAADC for all the animals, except for a single animal in the control group whose titer was 1:50 (Supplementary Table 8). At necropsy, anti-AAV2 antibody titers in control and AAV2-hAADC low-dose groups remained 1:25. However, animals in AAV2-hAADC high-dose group presented titers between 1:50 and 1:1,600, regardless of survival time. Neutralizing AAV2 antibodies are not anticipated to cause any adverse effects but could affect subsequent AAV-mediated gene transfer if repeated dosing with the same serotype were to be considered.

Regarding anti-hAADC antibodies, all animals showed antibodies against AADC protein in baseline samples, suggesting a natural presence of a reactive antibody in naïve animals (endogenous-load, Supplementary Fig. 5). Measurements of antibody titers against AADC

protein at the time of necropsy showed no substantial increase when compared to baseline levels in either the controls or AAV2-hAADC-treated animals, regardless of the dose (Supplementary Fig. 5). This result (ratio: ~1.0) indicates that parenchymal delivery of AAV2-hAADC did not induce anti-AADC antibodies.

## DISCUSSION

The purpose of this study was to investigate the safety and tolerability of a single-dose of AAV2-hAADC delivered into the mid-brain of NHP as a possible gene therapy for AADC deficiency. Previous studies on the striatal administration of AAV2-hAADC in NHP<sup>15-19</sup> and PD patients<sup>7, 8, 20, 21</sup>, support the use of this vector for the treatment of AADC deficiency. A Phase I study was conducted in Taiwan where 4 AADC deficiency patients that received a striatal AAV2-hAADC infusion showed improved motor function<sup>9</sup>. The investigators suggested that only partial motor improvement was observed in these patients due to sub-optimal coverage of the structure. However, an alternate explanation is that AAV2-hAADC transduces medium spiny neurons when infused into putamen. These cells do not synthesize appreciable amounts of L-DOPA, the substrate for AADC-catalyzed dopamine and serotonin synthesis. Thus, optimal improvement in motor function would not be expected in the absence of exogenous L-DOPA. The investigators did report elevated CSF levels of L-DOPA and presumably the transgenic AADC was able to make use of that<sup>9</sup>. However, the intracellular concentration of L-DOPA in medium spiny neurons in that context would probably be low. In contrast, L-DOPA is produced in the SNpc and VTA, and AADC-deficient patients, in contrast to PD patients, have an intact nigrostriatal pathway<sup>1</sup>. Thus, AAV2-hAADC transduction of SNpc and VTA should result in the replacement of the missing enzyme in the cells that would already make L-DOPA in abundance<sup>22</sup> and would thus be expected to direct dopamine synthesis as efficiently as in normal children. As there is currently no vertebrate animal model of AADC deficiency, we performed this toxicology study in naïve NHP and did not look for efficacy outcomes. However, we have previously demonstrated the functionality of this AAV2-hAADC vector in rats<sup>31</sup> and we also performed an *in vitro* assay that confirmed the increased conversion of L-DOPA to dopamine in cells transduced with the present AAV2-hAADC vector (Supplementary Fig. 2).

Our present data demonstrate that this vector can be safely delivered to SNpc and VTA with the FDA-approved SmartFlow cannula specifically designed for clinical application<sup>13, 14</sup>, with no appearance of adverse effects for up to 9 months after the procedure. The reliability of the SmartFlow cannula and direct delivery procedure we used is demonstrable in the small standard deviation of Vd/Vi data among the 36 infusions performed in this study. Reliable delivery is critical when targeting brain regions like the mid-brain, that contain many brain nuclei, in order to minimize off-target distribution and potential adverse effects. All animals receiving AAV2-hAADC showed good coverage of the target structures. Although MR tracer images could not be directly matched with AADC staining due to endogenous AADC expression, enhanced hAADC expression was detected in the same mid-brain regions as the MR tracer, including the SNpr which does not normally express this enzyme. Furthermore, AAV2-hAADC-treated animals' striata showed a wide network of strongly AADC-ir fibers in comparison to the significantly fainter endogenous AADC

staining in control animals. These data confirmed the cytoplasmic distribution of the transgenic protein in nigral axonal projections to striatum. In some cases, cannula placement was slightly lateral and the infusion did not properly reach VTA, resulting in a lack of transduction of this area. This would explain the lack of AADC-ir fibers in the nucleus accumbens. One aim of this study was to reveal exactly this type of anomaly. Therefore, our planned clinical trial will include 2 infusion sites: one in the SN and another in the VTA. The corresponding structures (i.e., SNpc and VTA) in human children are approximately 10-fold greater in volume than in NHP<sup>23</sup>. Thus, allowing for structural differences as well as clinical experience from our AAV2-hAADC studies in PD and the Taiwanese AADC deficiency, we estimate that a volume of 50  $\mu$ L in the SNpc would be optimal and the corresponding volume to be delivered in AADC-deficient children (on each side). Interestingly, one of the pilot animals received almost 50  $\mu$ L on the right SNpc and no behavioral or histological adverse effects were reported up to 1 month after the infusion, indicating that higher volumes than those in our toxicology study are likely to be safe.

Transduction of SNpc and VTA with this approach yielded broad expression of transgenic AADC in the nigro-striatum. There were no behavioral symptoms reported in any of the animals, control or AAV2-hAADC-treated, for either 1-, 3- or 9-month survival times. Accordingly, no histological indications of parenchymal injury due to cannula insertion, other than the expected gliosis and macrophages, were found despite 2 cannula insertions occurring close to each other in the mid-brain of every animal. An independent histopathology report found that some perivascular infiltrates were associated with AAV2-hAADC infusion. However, such infiltrates were also present in control animals. This type of response to the surgical injury seems to be caused by cannula insertion. In our experience, it resolves over time and has no persistent associated pathology<sup>18</sup>.

Assessment of vector distribution revealed that systemic exposure occurred during or immediately after AAV2-hAADC high vector dose delivery, but vector DNA was cleared from blood by the time of necropsy. Also, evaluation of CSF samples at baseline and necropsy showed no significant changes in dopamine, serotonin and their metabolites after AADC gene transfer indicating that AADC activity was likely localized in areas of observed AADC expression within the brain. Similarly, serum and CSF levels of AADC protein were not generally affected by AAV2-hAADC delivery. Taken together, all these data demonstrate the safety of the surgical procedure and long-term expression of AAV2-hAADC in the mid-brain.

A recent follow-up imaging study on PD patients from the AAV2-hAADC Phase I trial, demonstrated stable AADC expression by positron emission tomography with [18F]fluoro-L-metatyrosine tracer and continued safety over 4 years after vector delivery<sup>21</sup>. Accordingly, in the present study, AAV2-hAADC delivery in the mid-brain and wide AADC expression in the striatum for up to 9 months after delivery was accompanied by no severe adverse effects and was well-tolerated for up to 9 months.

Mutations in the *DDC* gene that cause AADC deficiency pathology cause a profound deficit in AADC enzyme in the brain (and peripheral organs), not only in the SNpc and VTA but also in the raphe nuclei that synthesizes serotonin. Thus, disease symptoms include not only



motor deficits but also mental retardation and autonomic dysfunction<sup>3,24</sup>. The approach presented in this study aims to alleviate the motor symptoms in AADC deficiency patients, but they may also further benefit from AAV2-hAADC delivery into the raphe nuclei. Since subsequent treatments in this brain region could be performed in patients who would have already received a primary SN/VTA infusion, the potential impact of anti-AAV2 and anti-hAADC antibodies was investigated. Although no significant antibody titer was found against AADC for any of the experimental groups, production of anti-AAV2 neutralizing antibodies was dose-dependent with antibodies detected only in the high-dose animals. Neutralizing anti-AAV2 antibodies are not anticipated to cause any adverse effects below a titer of 1:1200<sup>25</sup>, but could inhibit subsequent AAV2-mediated gene transfer if higher titers were generated. This potential problem could be overcome perhaps by using a different AAV serotype to carry the hAADC transgene, although cross-reactivity of anti-AAV2 antibodies could still be an issue<sup>26</sup>. Another potential concern often voiced by investigators in the field of recessive genetic diseases is the idea that introducing a protein never seen by the immune system might trigger immunity against the transgene. However, this consideration, perhaps concerning in other types of therapies, is considered unlikely in this situation because AAV2 is neuron-specific when infused into the brain and, as we have shown, is highly contained within target structures when our high-precision system is employed.

Altogether, this study demonstrates the long-term safety and tolerability of a single-dose administration of AAV2-hAADC into the mid-brain of NHP by real-time image-guided infusion. The data are supportive of clinical evaluation of this gene therapy in AADC deficiency disease.

## MATERIALS AND METHODS

### Animals

Eighteen adult Cynomolgus monkeys (*Macaca fascicularis*, 3-7 kg, 9 males, 9 females) were included in the present study. Individual animals were assigned to 2 experiments: an initial pilot study to examine vector distribution, dose-ranging and initial safety after delivery into the mid-brain (N=2) and a pivotal safety and toxicology study, performed in accord with Good Laboratory Practice standards, with a maximum in-life duration of 9 months after vector administration [Control group (vehicle, N=4), AAV2-hAADC low-dose group (N=6) and high-dose group (N=6)]. In the latter experiment, animals were assigned by random order selection; additional selection and distribution of animals across groups was made to obtain groups with comparable mean body weights. The animals received simultaneous bilateral infusion of either vehicle or AAV2-hAADC (low or high dose) into the SNpc and VTA and were monitored for either 1, 3 or 9 months after infusion (Table 1).

### In-life observations

Cage-side observations were performed twice daily throughout the study to evaluate general health, appearance, and appetite of all animals. Animals were weighed prior to surgery, weekly for the first four weeks after surgery, and biweekly thereafter until the conclusion of the study. Also, a battery of neurobehavioral evaluations, designed to assess central/

peripheral nervous system status, was conducted by an examiner blinded to treatment group on all animals at baseline and prior to necropsy. Pilot animals were housed at the Laboratory Animal Research Center in the University of California San Francisco (San Francisco, CA) and the pivotal safety and toxicology study was performed at Valley Biosystems Inc. (VBS, West Sacramento, CA). Use of animals for these studies was approved by the Institutional Animal Care and Use Committee at University of California San Francisco and the VBS Animal Care and Use Committee, respectively, and in accordance to the National Institutes of Health guidelines.

### Vector production and preparation

Both control and test articles were manufactured at Children's Hospital of Philadelphia (Philadelphia, PA). The human AADC cDNA was cloned into an AAV2 shuttle plasmid, and a recombinant AAV2 containing hAADC under the control of the cytomegalovirus promoter was manufactured by the AAV Clinical Vector Core at Children's Hospital of Philadelphia via a Good Manufacturing Practice process-comparable lot as previously described<sup>27</sup>. Briefly, AAV2-hAADC was generated by helper virus free transfection of HEK293 cells, and the vector purified from harvested cells and medium after cell lysis and clarification by combined ion exchange chromatography and isopycnic CsCl gradient centrifugation, and then diafiltered by tangential flow filtration against 180 mM sodium chloride, 10 mM sodium phosphate, pH 7.3 and concentrated to a final concentration of approximately  $8.3 \times 10^{12}$  vector genomes (vg)/mL. After TFF, Pluronic F68 was added to a final concentration of 0.001%. The test article was thawed and diluted with excipient (180 mM sodium chloride, 10 mM sodium phosphate, 0.001% v/v Pluronic F68, pH 7.3) to achieve the designated concentrations immediately prior to dosing (low dose:  $8.3 \times 10^{11}$  vg/mL; high dose:  $8.3 \times 10^{12}$  vg/mL). Gadoteridol (ProHance<sup>®</sup>, Bracco Diagnostics, Princeton, NJ), a magnetic resonance (MR) contrast agent, was added to the dosing solutions at a concentration of 2 mM (1:250 dilution of ProHance) to enhance visibility of the infusion on MR. Vector functionality was assayed by measuring the conversion of L-DOPA to dopamine *in vitro* (Supplementary Materials and Methods).

### Surgical procedure and image-guided delivery

Animals were sedated with an intramuscular injection of ketamine (10 mg/kg) and medetomidine (0.015 mg/kg). A tracheal intubation procedure was performed and the animals were placed on inhaled isoflurane (1-4%).

Each NHP was placed supine in a MRI-compatible stereotactic frame. After craniectomy, an adjustable MRI-compatible cannula trajectory guide device was secured to the skull over each hemisphere. After placement of the cannula guides, the intubated animal was moved into a 1.5T GE MRI scanner. High-resolution anatomical MR scans were performed for target identification and surgical planning.

Once the target was selected and cannula guides were aligned to the desired trajectory, SmartFlow<sup>®</sup> cannulae (MRI Interventions, Irvine, CA) custom-designed for pressurized infusions<sup>28, 29</sup> were used to infuse the vector. Each SmartFlow cannula was attached to a 1-mL syringe mounted onto a MRI-compatible infusion pump (Medfusion<sup>®</sup> 3500 syringe

pump, Medfusion, St. Paul, MN). Briefly, pumps were started at 1  $\mu\text{L}/\text{min}$  and, after visualizing fluid flow from the cannula tip when held at the height of the NHP head, the cannula was inserted through the cannula-guide and into the brain to the target depth. In the pilot study, one animal received 26  $\mu\text{L}$  on left side and 46  $\mu\text{L}$  on the right, and the second animal received 30  $\mu\text{L}$  on the left and 28  $\mu\text{L}$  on the right. The infusion rate was stepped up from 1  $\mu\text{L}/\text{min}$  to 2  $\mu\text{L}/\text{min}$  based on real-time MR images of the gadolinium signal during the infusion. In the IND-enabling toxicology study, all animals received a uniform volume of 30  $\mu\text{L}$  to each side (60  $\mu\text{L}$  total) at an initial rate of 1  $\mu\text{L}/\text{min}$  for 10 min followed by a rate of 2  $\mu\text{L}/\text{min}$  for 10 min. Immediately after completion of the MRI-guided infusions, each animal was returned to surgery where the cannula guides were removed and incisions sutured. Then, animals were moved to their home-cage and monitored for full recovery from anesthesia.

### MR imaging data analysis

Prior to cannula insertion, MR images were acquired via previously established methods to plan and determine precise placement of the infusion- and guide-cannula within the SNpc. Briefly, T1-weighted images of the primate brain were acquired on a 1.5T Signa HDxt scanner (GE Medical Systems, Waukesha, WI) with two 5-inch surface coils. Prior to insertion of the SmartFlow cannulae, baseline 3-dimensional spoiled gradient echo (3D SPGR) images were taken: repetition time (TR)/echo time (TE)/flip angle = 3.9 ms/1.54 ms/15°, number of excitations (NEX) = 4, matrix = 256  $\times$  192, field of view (FOV) = 16 cm  $\times$  12 cm, slice thickness = 1 mm. Once the catheters were inserted and the infusion commenced, SPGR scans were acquired consecutively throughout the infusion procedure (acquisition time was ~2.5 min per sequence) to monitor distribution from the cannula tip. Distribution volumes (Vd) of gadolinium were measured on MR images with Osirix® (Geneva, Switzerland), an open source DICOM reader and imaging workstation. Software was written and applied as an Osirix plug-in to auto-segment each infusion on individual MRI slices from which a total distribution volume was calculated<sup>30</sup>. The ratio (Vd/Vi) between volume of distribution (Vd) and the infusion volume (Vi) was calculated for each hemisphere in all animals and data presented as mean  $\pm$  standard deviation for each hemisphere. The gadolinium-enhanced regions on the images were also visualized using iPlan 3.0.3 workstation (Brainlab; Munich, Germany). The workflow used standard semi-automatic segmentation (iPlan Smartbrush) to generate 3-dimensional reconstructions of the infusate distribution. A blinded intraoperative correlation validated the reconstruction results of enhanced regions and cannula trajectory for each group assignment.

### Histopathological analysis

Animals were euthanized either 1, 3 or 9 months after intracranial dosing procedures (Table 1) by transcardial perfusion with either PBS-heparin and 4% paraformaldehyde (PFA)/PBS (pilot study) or PBS-heparin alone (toxicology study). Gross necropsy and tissue examinations were performed by a veterinary pathologist for both studies. For the pilot study, brains and spinal cord samples were collected and post-fixed in 4% PFA overnight. Brain-blocks were then cut into 40- $\mu\text{m}$  sections in a sliding microtome and cryopreserved in anti-freeze solution until further analysis. For the IND-enabling toxicology study, the brain and spinal cord were blocked and immersion-fixed in 4% PFA and samples of major

peripheral organs were immersion-fixed in 10% formalin. Brain-blocks containing either SNpc/VTA (infusion site), basal ganglia (striatum, globus pallidus, subthalamic nucleus), thalamus, brainstem, cortex, spinal cord and peripheral organs samples were subjected to histopathology analysis by an independent pathology group (Seventh Wave Laboratories, LLC) blinded to treatment groups.

### Histological analysis of transgene expression

To assess transgene expression, brain sections from both studies were processed for double immunohistochemistry (IHC) with antibodies to detect AADC protein (endogenous and transgenic) and tyrosine hydroxylase (TH), the latter a counterstain to identify striatum, SNpc and VTA.

Briefly, sections were first de-paraffinized, if needed, in Clear Rite 3 (Thermo Scientific, Waltham, MA) and graded alcohols, rehydrated and treated for antigen-retrieval in Diva Decloaker solution (Biocare Medical, Concord, CA) in a decloaking chamber. Sections were washed in Tris-buffered saline (TBS) followed by treatment with 1.5% v/v H<sub>2</sub>O<sub>2</sub> in TBS to block endogenous peroxidase. Sections were then incubated in Sniper<sup>®</sup> blocking solution (Biocare Medical, Concord, CA) followed by incubation overnight at 4°C with primary antibodies (rabbit polyclonal anti-DDC, 1:1,000, cat. AB136 and anti-TH, 1:5,000, cat. MAB 318, Millipore, Billerica, MA). Sections were rinsed in TBS and incubated in Mach 2 Rabbit HRP Polymer (Biocare Medical, Concord, CA) and Mouse AP Polymer (Biocare Medical, Concord, CA) for 1 h, followed by several washes and colorimetric development with Vector Blue (Vector Blue Alkaline Phosphatase substrate kit, cat. SK-5300; Burlingame, CA) and either Vector NovaRED (Vector NovaRED Peroxidase substrate kit, cat. SK-4800; Burlingame, CA) or 3,3'-diaminobenzidine (DAB Peroxidase substrate kit, cat. SK-4100; Burlingame, CA). Immunostained sections were dehydrated in graded alcohols and or Clear Rite 3 and cover-slipped with a toluene-based mounting media (Shandon-Mount, Thermo Scientific, Waltham, MA). For hematoxylin and eosin (H&E) staining, sections were de-paraffinized if needed, rehydrated and stained with hematoxylin (Buffalo Grove, IL) for 3 min, washed with water and then differentiated in 0.5% v/v acetic acid/70% alcohol followed by staining in bluing solution (Thermo Scientific, Waltham, MA). After incubation in eosin (Buffalo Grove, IL), the sections were dehydrated in alcohol and xylene, and cover-slipped.

Transgene expression analysis was performed for both the pilot and toxicological studies. For the pilot study sections, the SNpc/VTA and striatum were double-stained to assess vector distribution and transgenic protein transport to neuronal terminals. For the toxicological study, transgenic AADC expression was analyzed as follows. For AADC expression in the striatum, coronal sections (N=4 per animal) containing pre-commissural, commissural and post-commissural striatum were analyzed for AADC expression in nigrostriatal projections. Endogenous AADC immunoreactivity (ir) observed in the striatum of control animals was significantly lower than that from transgenic AADC expression in AAV2-hAADC treated animals, thereby permitting reliable detection of transgenic hAADC expression in striatum. AADC-ir in control group sections was used as a reference for the assessment of the expression of hAADC in treated animals (low-dose and high-dose

groups). In order to evaluate transgenic hAADC protein distribution, doubly stained striatal sections were rated for the presence of fibers expressing hAADC in both caudate and putamen (-: absent (endogenous AADC staining); +: low intensity / sparse fiber staining; ++: intermediate intensity / many positive fibers; +++: high intensity / dense fiber staining).

For AADC expression in structures outside the infusion target, coronal sections (N=4 per animal) containing basal ganglia and other nuclei were analyzed for AADC expression. AADC-ir in control group sections was used as the reference for the assessment of the off-target expression of transgenic AADC in AAV2-hAADC treated animals (low-dose and high-dose groups). Sections were checked for transgenic hAADC expression in basal ganglia (other than striatum), brainstem and spinal cord. High levels of endogenous AADC protein did not permit assessment of transgenic hAADC expression in VTA and SNpc. All histological analysis of all sections was performed by observers blind to treatment group identities.

### Blood and cerebrospinal fluid sampling

Serum samples were collected for hematology, clinical pathology, AADC levels and vector distribution at baseline, 4 hours, 24 hours, 15 days, 1, 3, 6 and 9 months from the toxicology study animals only. Serum samples for anti-AAV2 and anti-AADC antibody detection were collected at baseline, day 15, and at necropsy. Whole blood samples (0.5 mL) were collected in EDTA tubes and stored at 4°C until further processing. Similarly, blood for serum samples from the animals in the toxicology study were collected in serum separator tubes with clot activator, allowed to clot for 30 min and spun for 15 min at 3,000 rpm. Serum was transferred to tubes with no additive and frozen until further use.

In the same animals, CSF was collected prior to parenchymal dosing procedures and immediately prior to necropsy for monoamines and AADC protein assessment. All CSF samples were collected in sterile 1.5 mL centrifuge tubes, except those for vector biodistribution that were collected in DNase- and RNase-free sterile 1.5 mL centrifuge tubes. Both blood serum and CSF samples were collected for assay of anti-AAV2 and anti-AADC antibodies.

### Monoamine level assessment (HPLC) in CSF

Monoamine levels were measured in CSF at baseline and at necropsy for toxicological study animals. Ice-cold 7 M perchloric acid (1.5 µL) was added to each CSF sample (100 µL). Samples were then vortexed and centrifuged at 14,000 rpm for 15 min at 4°C. The supernatant was transferred to a 1.5 mL centrifuge tube and centrifuged again as above. The supernatant was then filtered through a 0.20 µm membrane syringe Whatman filter (Sigma Aldrich, St. Louis, MO) and injected onto high-performance liquid chromatography (HPLC) system coupled to electrochemical detection (ECD, CoulArray® 5600A, ESA, Chelmsford, MA) for determination of dopamine, DOPAC, HVA, serotonin and 5-HIAA.

Supernatant (30 µL) was injected onto the HPLC-ECD system as previously described<sup>31</sup>. In parallel with CSF samples, a series of standard solutions (Sigma Aldrich, St. Louis, MO) with known concentrations of these catecholamines (1000 ng/mL, 100 ng/mL and 20 ng/mL) were also chromatographed. Dopamine, DOPAC, HVA, serotonin and 5-HIAA in

CSF samples were identified by retention times of standards and quantified by measuring the area under the peaks with CoulArray® Data Station 3.00 software (ESA, Chelmsford, MA). The limit of quantification was set at 10 ng/mL. Concentrations (ng/mL) in CSF samples were reported by comparison with the standard curves.

### **AADC protein levels and AAV2-hAADC biodistribution in serum and CSF**

Serum samples taken at baseline, 4 hours, 24 hours, 15 days, 1, 3, 6 and 9 months after infusion were analyzed for AADC levels and biodistribution. CSF was collected only at baseline and at necropsy for these analyses.

Quantification of AADC protein in serum and CSF samples was performed by sandwich ELISA assay as previously described. A commercially available kit “Human DOPA Decarboxylase/DDC ELISA Pair Set” (Sino Biological Inc., Beijing, China) was used for this assay. ELISA was performed according to the manufacturer’s protocol. Absorbance (TMB substrate) at 450 nm was proportionate to the amount of AADC present in the sample. The minimum detectable concentration of AADC in the assay was determined to be 62.5 pg/mL.

Quantitative polymerase chain reaction (Q-PCR) of AAV2-hAADC vector DNA in serum and CSF samples at baseline and necropsy was performed with a fluorogenic 5' - nuclease assay (TaqMan®, Applied Biosystems, Foster City, CA) on an Applied Biosystems® ViiA™ 7 Real-Time PCR System (Applied Biosystems, Foster City, CA) as previously described<sup>32</sup>. Real-time Q-PCR was standardized with plasmid DNA containing the vector insert (pAAV-hAADC2; Lot# 3321850). The plasmid was linearized with EcoRV, purified, quantified by ultraviolet absorbance, and diluted in Q-PCR dilution buffer to generate 7 standards ranging from 10 to 1×10<sup>6</sup> copies/reaction. Each standard was run in 3 replicate 20-μL reactions in a 384-well optical plate. Genomic DNA was isolated from serum and CSF by means of QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA). To increase the yield of DNA isolation from cell-free serum and CSF samples, per manufacturer’s recommendation, carrier DNA (salmon sperm DNA) was added to Buffer AL (5 μg per 200 μL). A sentinel control sample (salmon sperm DNA alone) was also isolated at the same time to monitor for contamination. Genomic DNA isolated from each sample (200 μL of serum or CSF) was assayed for AAV2-hAADC. Of the total 50-μL DNA elute, 5 μL was assayed for AAV2-hAADC (each reaction). In addition, 3 random samples were spiked with 100 copies of the vector standard and assayed to monitor the PCR reaction efficiency. Samples with low reaction efficiency (<75%) were presumed to contain PCR inhibitors that affected sensitivity. In the presence of AAV2-hAADC DNA, the AAV2-hAADC-specific primers amplify a 70-base pair region of exon 7 and 8 of the AAV2-hAADC target (Life Technologies, Foster City, CA). Spanning an intron absent from the vector sequence minimizes amplification of genomic DNA. During the extension step at 60°C, the AAV2-hAADC-specific probe is incorporated into the amplicon and releases the attached 6-carboxyfluorescein. The amount of fluorescence generated is proportional to the number of AAV2-hAADC amplicons generated during the run, and is related to the initial amount of AAV2-hAADC template present in each sample. Human AADC cDNA copies were calculated by multiplying the copies per well by 2, assuming that 1 copy of double-stranded

plasmid DNA is equivalent to 2 single-stranded vector genomes. Upper and lower limits of quantitation were selected as the highest and lowest points on the standard curve ( $10 - 10^6$  copies and 10 copies of AAV2-hAADC per reaction, respectively).

### Anti-AAV2 and anti-AADC neutralizing antibody titers

To screen for AAV2 neutralizing activity in NHP serum, samples were collected prior to surgery (baseline) and at necropsy. The neutralizing titer was determined *in vitro* in a cell-based assay. Serum samples were serially diluted (lowest dilution 1:25) with DMEM culture medium containing 2% FBS and incubated with AAV2-green fluorescent protein (GFP),  $4 \times 10^8$  vg at 37°C. One hour after mixing the vector and serum samples, 50% of the mixture of serum/vector (20  $\mu$ L) was added (in triplicate) to HT1080 cells seeded the previous day at 20,000 cells per well (100  $\mu$ L) of 96-well plates (clear bottom, black walls). The final multiplicity of infection for each well was 10,000. In parallel, the same amount of vector but without NHP serum was added to cells for vector control standard. Blank (negative control) determinations omitted the vector. The cells were grown for 2 days and, after one wash in PBS, the level of GFP expression (fluorescence) was measured in a FL-800 Biotek plate reader (Biotek, Winooski, VT) with a green filter (488 nm). After subtracting the background (values of blank controls with no virus added), the mean values from each triplicate were calculated and compared with the positive control/standard (AAV2 with no NHP serum added). AAV2 neutralizing antibody titer is the highest dilution of serum that results in 50% reduction in fluorescence when compared with untreated vector.

Antibodies against AADC protein were detected in NHP serum by incubating serial dilutions of serum (1:2, 1:8, 1:32, 1:128, 1:512, 1:2048 and 1:8192) with 60 ng recombinant human AADC protein (R&D Systems, Minneapolis, MN) per well immobilized on wet nitrocellulose in a Bio-Dot Microfiltration apparatus (Bio-Rad, Hercules, CA) following the manufacturer's protocol. Serum samples were collected at baseline, at various in-life intervals (1, 3 and 9 months), and at necropsy. Horseradish peroxidase-conjugated goat anti-monkey IgG (Fitzgerald, Acton, MA) was used as a secondary antibody (1:5,000 dilution) and color development of enzyme-conjugated antibodies was performed by Immun-Blot<sup>®</sup> Opti-4CN<sup>™</sup> Colorimetric kit (Bio-Rad, Hercules, CA). Once dry, membranes were digitized and generated images were analyzed with ImageJ software<sup>33</sup>. The upper and lower limits of intensity for this assay were standardized to establish the dynamic range for ratio calculation as 20,000 to 5,000 arbitrary units, respectively.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments


The authors thank Valley Biosystems and Seventh Wave Laboratories for performing in-life evaluations and histopathology report, respectively. This work was supported by NIH grant X01 NS073514-01 to KSB, Pediatric Neurotransmitter Deficiency Foundation and AADC Trust Foundation, UK.

## References

1. Lee HF, Tsai CR, Chi CS, Chang TM, Lee HJ. Aromatic L-amino acid decarboxylase deficiency in Taiwan. *Eur J Paediatr Neurol.* 2009; 13:135–140. [PubMed: 18567514]
2. Manegold C, Hoffmann GF, Degen I, Ikonomidou H, Knust A, Laass MW, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. *J Inherit Metab Dis.* 2009; 32:371–380. [PubMed: 19172410]
3. Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. *J Inherit Metab Dis.* 1990; 13:301–304. [PubMed: 1700191]
4. Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. *Neurology.* 2010; 75:64–71. [PubMed: 20505134]
5. Hoffmann GF, Assmann B, Brautigam C, Dionisi-Vici C, Haussler M, de Klerk JB, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. *Ann Neurol.* 2003; 54(Suppl 6):S56–65. [PubMed: 12891655]
6. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. *Arch Neurol.* 1969; 21:343–354. [PubMed: 5820999]
7. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. *Neurology.* 2009; 73:1662–1669. [PubMed: 19828868]
8. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. *Mol Ther.* 2010; 18:1731–1735. [PubMed: 20606642]
9. Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. *Sci Transl Med.* 2012; 4:134ra161.
10. Johnston LC, Eberling J, Pivrotto P, Hadaczek P, Federoff HJ, Forsayeth J, et al. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. *Hum Gene Ther.* 2009; 20:497–510. [PubMed: 19203243]
11. Kells AP, Forsayeth J, Bankiewicz KS. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. *Neurobiol Dis.* 2012; 48:228–235. [PubMed: 22019719]
12. Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. *Mol Ther.* 2011; 19:922–927. [PubMed: 21102559]
13. Richardson RM, Gimenez F, Salegio EA, Su X, Bringas J, Berger MS, et al. T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. *Neurosurgery.* 2011; 69:154–163. discussion 163. [PubMed: 21430597]
14. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, Piferi PG, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. *Stereotact Funct Neurosurg.* 2011; 89:141–151. [PubMed: 21494065]
15. San Sebastian W, Richardson RM, Kells AP, Lamarre C, Bringas J, Pivrotto P, et al. Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. *Hum Gene Ther.* 2012; 23:210–217. [PubMed: 22017504]
16. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivrotto P, Bringas J, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. *Mol Ther.* 2006; 14:564–570. [PubMed: 16829205]
17. Forsayeth JR, Eberling JL, Sanftner LM, Zhen Z, Pivrotto P, Bringas J, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. *Mol Ther.* 2006; 14:571–577. [PubMed: 16781894]
18. Hadaczek P, Eberling JL, Pivrotto P, Bringas J, Forsayeth J, Bankiewicz KS. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. *Mol Ther.* 2010; 18:1458–1461. [PubMed: 20531394]




19. Daadi MM, Pivrotto P, Bringas J, Cunningham J, Forsayeth J, Eberling J, et al. Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. *Neuroreport*. 2006; 17:201–204. [PubMed: 16407771]
20. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology*. 2008; 70:1980–1983. [PubMed: 18401019]
21. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. *Hum Gene Ther*. 2012; 23:377–381. [PubMed: 22424171]
22. Dahlstroem A, Fuxe K. Evidence for the Existence of Monoamine-Containing Neurons in the Central Nervous System. I. Demonstration of Monoamines in the Cell Bodies of Brain Stem Neurons. *Acta Physiol Scand Suppl: SUPPL*. 1964; 232:231–255.
23. Yin D, Valles FE, Fiandaca MS, Forsayeth J, Larson P, Starr P, et al. Striatal volume differences between non-human and human primates. *J Neurosci Methods*. 2009; 176:200–205. [PubMed: 18809434]
24. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. *Neurology*. 1992; 42:1980–1988. [PubMed: 1357595]
25. Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR, et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. *Mol Ther*. 2004; 9:403–409. [PubMed: 15006607]
26. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. *J Infect Dis*. 2009; 199:381–390. [PubMed: 19133809]
27. Wright JF, Wellman J, High KA. Manufacturing and regulatory strategies for clinical AAV2-hRPE65. *Curr Gene Ther*. 2010; 10:341–349. [PubMed: 20712582]
28. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. *J Neurosurg*. 2005; 103:923–929. [PubMed: 16304999]
29. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. *Neurotherapeutics*. 2008; 5:123–127. [PubMed: 18164491]
30. Rosenbluth KH, Gimenez F, Kells AP, Salegio EA, Mittermeyer GM, Modera K, et al. Automated segmentation tool for brain infusions. *PLoS One*. 2013; 8:e64452.10.61371/journal.pone.0064452 [PubMed: 23755125]
31. Ciesielska A, Hadaczek P, Mittermeyer G, Zhou S, Wright JF, Bankiewicz KS, et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. *Mol Ther*. 2013; 21:158–166. [PubMed: 22929660]
32. Cunningham J, Pivrotto P, Bringas J, Suzuki B, Vijay S, Sanftner L, et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. *Mol Ther*. 2008; 16:1267–1275. [PubMed: 18523450]
33. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods*. 2012; 9:671–675. [PubMed: 22930834]



Study	Infusion volume (per site)	Vd/Vi
Pilot	26-46 $\mu$ L	2.23 $\pm$ 0.24
GLP toxicology	30 $\mu$ L	2.18 $\pm$ 0.52

**Figure 1. Reproducibility magnetic resonance (MR) image-guided infusion of AAV2-hAADC into the primate mid-brain**


Top panel shows representative coronal MR images of AAV2-hAADC after pressure-driven delivery in each animal. Notice there was slight reflux in only 2 out of 36 infusion performed (V002458 and V002254). Summary table below presents diffusion volume/infusion volume ratio (Vd/Vi, mean  $\pm$  standard deviation) for pilot and toxicology groups.




**Figure 2. Surgery and vector-related histological findings**

Independent evaluation of hematoxylin and eosin (H&E) staining of coronal sections containing the cannula tract revealed normal gliosis related to cannula insertion in all experimental groups (arrowheads). Higher magnification images (right column) were taken close to the cannula tip (black arrows in left column). H&E staining also showed perivascular cellular infiltrates in AAV2-hAADC-treated, but not PBS-treated, animals regardless of survival time. Although incidence and severity of perivascular cuffs was increased with AAV2-hAADC vector dose, these were not considered adverse. Note that there were also many vessels with no perivascular cuffing close to the infusion site (white

arrows in left column) and that perivascular cellular infiltrates were not present in the pilot AAV2-hAADC animal. Scale bars: left column: 1 cm; right column: 100  $\mu$ m.



**Figure 3. AADC expression in the mid-brain pilot (a) and toxicology (b) study animals**  
 AADC staining of mid-brain revealed good correlation between infusate (gadolinium) signal in MRI and AAV2-hAADC expression (left and middle columns). AADC signal (brown) in SNpc and VTA that co-localized with endogenous tyrosine hydroxylase signal (blue, middle column). Although transgenic AADC in these nuclei was indistinguishable from endogenous AADC, AAV2-hAADC gene product was easily visible in SNpr when compared to naïve animal images. Higher magnification images show transgenic AADC staining in cells and fibers (right column). Scale bars: Left and middle columns: 1 cm; right column: 200  $\mu$ m.



**Figure 4. Axonal transport of AADC protein through the nigrostriatal pathway**

Double immunohistochemical staining for TH (blue) and AADC (brown) in the striatum demonstrated the presence of the transgenic AADC in nigrostriatal terminals that widely covered both caudate and putamen nuclei. High-magnification images show the intensity of AADC staining in transduced fibers in AAV2-hAADC-treated animals compared to endogenous signal in PBS control group. Black squares indicate the area shown in higher magnification images. Notice the similar fiber density for both low and high AAV2-hAADC doses. Scale bar: 100  $\mu$ m.

Table 1

Dosing groups and necropsy schedule

<i>Pilot study</i>				
Group	Vector conc. (vg/mL)	Vector dose (vg)	Survival time	
AAV2-hAADC High dose	$8.3 \times 10^{12}$	$5.0 \times 10^{11}$ - $6.0 \times 10^{11}$	1 month (n=2, Female)	
<i>Pivotal Toxicology study</i>				
Group	Vector conc. (vg/mL)	Vector dose (vg)	Survival time groups (Male + Female)	
Control	0	0	1 month (n=5) 1 Male	3 months (n=5) 1 Male
AAV2-hAADC Low dose	$8.3 \times 10^{11}$	$5.0 \times 10^{10}$	2(1+1)	2(1+1)
AAV2-hAADC High dose	$8.3 \times 10^{12}$	$5.0 \times 10^{11}$	2(1+1)	2(1+1)

Abbreviations: Conc.: concentration, vg: vector genome.

**Table 2**

Transgenic AADC-positive fibers in striatum (caudate nucleus and putamen) and nucleus accumbens

NHP ID	Caudate nucleus	Putamen	Nucleus accumbens <sup>a</sup>
<b>Control group</b>			
V002326 (1M)	-	-	-
V002215 (1M)	-	-	-
V002397 (3M)	-	-	-
V002458 (9M)	-	-	-
<b>AAV2-hAADC Low dose group</b>			
V002243 (1M)	+++	+++	-
V002274 (1M)	++/+++	++/+++	-
V002254 (3M)	+	+	-
V002294 (3M)	++/+++	++/+++	+
V002100 (9M)	+++	++	++
V002276 (9M)	+++	++	
<b>AAV2-hAADC High dose</b>			
V002332 (1M)	+++	++	-
V002370 (1M)	++/+++	++/+++	-
V002224 (3M)	+++	++/+++	+
V002304 (3M)	++/+++	++	-
V002325 (9M)	++	+/++	-
V002450 (9M)	+++	+++	+

AADC-ir fiber staining rating: -: absent (endogenous AADC staining); +: low intensity / sparse fiber staining; ++: intermediate intensity / many positive fibers; +++: high intensity / dense fiber staining. Abbreviations: M: months.

<sup>a</sup> AADC-positive fibers were found only in nucleus accumbens core.



**Table 3**

Off-target expression of transgenic hAADC protein

Brain structure	AAV2-hAADC Low dose	AAV2-hAADC High dose
Globus pallidus	F	F
Thalamus	F/C <sup>a</sup>	F/C <sup>a</sup>
Medial forebrain bundle	-	F
Subthalamic nucleus	F/C <sup>a</sup>	F/C <sup>a</sup>
Substantia nigra pars reticulata	F	F
Red nucleus	F/C	F/C
Spinal cord	-	F
Other	F Corona radiata/IC Area dorsal to SN	F Corona radiata/IC Area dorsal to SN

<sup>a</sup>Surrounding cannula tract. Abbreviations: C: cells; F: fibers; IC: internal capsule.